Phathom Pharmaceuticals, Inc. (PHAT)

Search for stocks, ETFs, and funds for a quick comparison or use the comparison tool for more options.

The chart shows the growth of an initial investment of $10,000 in Phathom Pharmaceuticals, Inc., comparing it to the performance of the S&P 500 index or another benchmark. All prices have been adjusted for splits and dividends.

Phathom Pharmaceuticals, Inc. (PHAT) has returned -33.03% so far this year and 77.19% over the past 12 months.

Based on dividend-adjusted daily data since Oct 25, 2019, PHAT's average daily return is +0.11%, while the average monthly return is +1.64%. At this rate, your investment would double in approximately 3.6 years.

Historically, 49% of months were positive and 51% were negative. The best month was Jun 2025 with a return of +125.7%, while the worst month was Nov 2024 at -48.3%. The longest winning streak lasted 5 consecutive months, and the longest losing streak was 5 months.

On a daily basis, PHAT closed higher 49% of trading days. The best single day was Jun 6, 2025 with a return of +90.2%, while the worst single day was Jan 4, 2023 at -31.1%.

Phathom Pharmaceuticals, Inc. has an annualized alpha of 9.72%, beta of 1.36, and R² of 0.09 versus S&P 500 Index. Calculated based on daily prices since October 28, 2019.

• This stock participated in 127.47% of S&P 500 Index downside but only 37.12% of its upside — more exposed to losses than it benefited from rallies.
• R² of 0.09 means this stock moves largely independently of S&P 500 Index — capture ratios reflect limited market correlation rather than active downside protection. Consider using a more representative benchmark.

PHAT ranks 70 for risk / return — better than 70% of stocks on our site. You're getting solid returns for the risk taken. A good sign, especially for investors who want growth without excessive volatility.

The table below present risk-adjusted performance metrics for Phathom Pharmaceuticals, Inc. (PHAT) and compare them to a chosen benchmark (S&P 500 Index).

The Drawdowns chart displays portfolio losses from any high point along the way. Drawdowns are calculated considering price movements and all distributions paid, if any.

The table below displays the maximum drawdowns of the Phathom Pharmaceuticals, Inc.. A maximum drawdown is a measure of risk, indicating the largest reduction in portfolio value due to a series of losing trades.

The maximum drawdown for the Phathom Pharmaceuticals, Inc. was 95.81%, occurring on May 8, 2025. The portfolio has not yet recovered.

The current Phathom Pharmaceuticals, Inc. drawdown is 79.65%.

The chart below shows the rolling one-month volatility.

The chart below illustrates the trends in the financial health of Phathom Pharmaceuticals, Inc. over time, highlighting three key metrics: Total Revenue, Earnings Before Interest and Taxes (EBIT), and Net Income.

The Valuation section provides an overview of how Phathom Pharmaceuticals, Inc. is priced in the market compared to other companies in the Biotechnology industry. It includes key financial ratios that help investors assess whether the stock is undervalued or overvalued.